{"id":39913,"date":"2026-10-17T10:49:00","date_gmt":"2026-10-17T14:49:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39913"},"modified":"2026-10-15T08:50:23","modified_gmt":"2026-10-15T12:50:23","slug":"the-philippines-pharma-opportunity-map-what-patent-expirations-can-and-cannot-tell-you","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-philippines-pharma-opportunity-map-what-patent-expirations-can-and-cannot-tell-you\/","title":{"rendered":"The Philippines Pharma Opportunity Map: What Patent Expirations Can and Cannot Tell You"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

In 2024, the Intellectual Property Office of the Philippines (IPOPHL) granted 2,063 patents. Non-residents received 1,958 of them. That is 94.9% (calculated from the WIPO table in [7]). Almost every Philippine drug patent is therefore a foreign filing. If you read a patent expiration date for the Philippines as a local event, you start with the wrong picture.<\/p>\n\n\n\n

This article shows how to read a Philippine patent expiration date. It also shows where the date stops being useful. The Philippines has no patent linkage, no data exclusivity rules, and no patent term extension for drugs. Its patent law also limits secondary patents on known molecules. These rules make a patent date more informative in some ways and less informative in others. We assemble the legal record, the filing statistics, two court cases, two price-cap orders, and one live product case (semaglutide). We then give an original five-gate model for turning an expiry date into a decision.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

A Philippine patent expiration date tells you when the patent owner loses the right to block sales. It does not tell you when a generic reaches a patient. Four things sit between the two: registration with the Food and Drug Administration (FDA), price regulation, procurement channels, and the supply of active pharmaceutical ingredient (API). The date is the start of the work, not the end.<\/p>\n\n\n\n

The Five Findings That Matter<\/strong><\/h2>\n\n\n\n

Finding 1: Foreign Owners Hold Almost All Granted Patents<\/strong><\/h3>\n\n\n\n

In 2024, non-residents received 1,958 of 2,063 granted patents in the Philippines. Residents received 105. Non-residents therefore held 94.9% of grants (our calculation from [7]).<\/p>\n\n\n\n

Finding 2: Pharmaceuticals Lead Patent Filings<\/strong><\/h3>\n\n\n\n

IPOPHL data reported by The Philippine Star show that pharmaceuticals led patent filings in 2025 at 24.9%. Total patent filings were 4,486. We estimate about 1,117 pharmaceutical filings (4,486 x 0.249; our calculation from [8]).<\/p>\n\n\n\n

Finding 3: No Linkage, No Data Exclusivity Rules<\/strong><\/h3>\n\n\n\n

Chambers reports that the Philippines eliminated patent linkage in 2006. It also reports that no specific law or rule covers data or market exclusivity. [3] The FDA can approve a generic without a patent check.<\/p>\n\n\n\n

Finding 4: Courts Move Slower Than Patents Expire<\/strong><\/h3>\n\n\n\n

In Philippine Pharmawealth v. Pfizer, the patent expired on July 16, 2004. The Supreme Court decided the case on November 17, 2010. [13] That is six years and four months after expiry (our calculation). In the telmisartan case, the Bureau of Legal Affairs took about six years from the 2015 complaint to the June 25, 2021 decision. [14]<\/p>\n\n\n\n

Finding 5: Two Orders Cap Prices on 204 Drug Formulas<\/strong><\/h3>\n\n\n\n

Executive Order 104 (2020) covers 133 drug formulas. [9] Executive Order 155 (2021) adds 71. [10] The total is 204 formulas (our sum). A price cap narrows the gap between a brand and a generic after expiry.<\/p>\n\n\n\n

Methodology and Definitions<\/strong><\/h2>\n\n\n\n

What Data We Analyzed<\/strong><\/h3>\n\n\n\n

We used primary legal texts where we could reach them: Republic Act No. 9502 [1], Executive Orders 104 and 155 [9][10], and the Supreme Court decision in Pharmawealth [13]. We used IPOPHL statistics through WIPO [7] and a press report of IPOPHL data [8]. We used practitioner guides for points that the statutes do not state in one place [3][4][5]. We used DrugPatentWatch (DPW) as a secondary data source and tested its Philippines page against the legal record [15][16].<\/p>\n\n\n\n

How We Calculated<\/strong><\/h3>\n\n\n\n

Every derived figure carries the label “our calculation.” Percentages use the source numbers without rounding before division. Time spans use the dates in the cited source. Working-day conversions assume five working days per week and exclude time the applicant spends answering deficiency notices.<\/p>\n\n\n\n

Limits of This Analysis<\/strong><\/h3>\n\n\n\n

We did not search the IPOPHL patent register patent by patent. IPOPHL declined a 2022 Freedom of Information request for patent status on two drugs and pointed the requester to a paid search service. [20] We therefore do not publish a full list of expiring Philippine drug patents. Several practitioner sources are law firm or consultancy articles. We label them as such. The telmisartan decision is under appeal in the source we used. [14]<\/p>\n\n\n\n

Definitions<\/strong><\/h3>\n\n\n\n

Patent expiration date: the last day on which a patent can be enforced. Loss of exclusivity (LOE): the date on which competitors can sell without legal bar. Patent linkage: a rule that ties drug marketing approval to patent status. Parallel importation: the import of a genuine product that the patent owner sold in another country. Branded generic: a generic product sold under a company brand name.<\/p>\n\n\n\n

How Do Philippine Pharmaceutical Patents Work?<\/strong><\/h2>\n\n\n\n

How Long Does a Drug Patent Last in the Philippines?<\/strong><\/h3>\n\n\n\n

A patent lasts 20 years from the filing date. The term is not renewable. [5] A utility model lasts seven years from filing. [5] The clock runs from filing, not from grant, so a slow examination does not extend protection.<\/p>\n\n\n\n

Older patents follow older rules. Pfizer’s Philippine Patent No. 21116 issued on July 16, 1987, and Pfizer admitted that it was valid until July 16, 2004. [13] That is 17 years from grant (our calculation). A date taken from a database for an old patent needs a check against the record.<\/p>\n\n\n\n

How Long Does Patent Grant Take?<\/strong><\/h4>\n\n\n\n

Legal 500 gives about three to five years for patent registration, depending on office actions and amendments. It gives 18 months from filing or priority for publication. [5] An applicant must also pay annual fees. A missed fee lapses the patent after a six-month grace period. [5]<\/p>\n\n\n\n

What Does the Philippine Law Say About New Forms of Known Drugs?<\/strong><\/h3>\n\n\n\n

Republic Act No. 9502 changed Section 22.1 of the IP Code. The “mere discovery of a new form or new property of a known substance” is not patentable unless it enhances known efficacy. Salts, esters, polymorphs, and isomers count as the same substance unless they differ significantly in efficacy. [1] Section 26.2 states that a mere new form, new property, or new use of a known substance involves no inventive step for drugs. [1]<\/p>\n\n\n\n

How Does IPOPHL Examine These Applications?<\/strong><\/h4>\n\n\n\n

IPOPHL published revised guidelines for pharmaceutical applications involving known substances in January 2018. [6] The guidelines say efficacy includes therapeutic effect and advantageous properties such as bioavailability, stability, or solubility. The applicant must give comparative data. The examiner may consult FDA experts, and their opinion does not bind the examiner. [6]<\/p>\n\n\n\n

What About Second Medical Use Claims?<\/strong><\/h4>\n\n\n\n

The guidelines require Swiss-type claim drafting for a second medical use. The use must treat a different pathology. Methods of treatment by therapy or surgery are excluded under Section 22.3. [6] Claims to products or compositions for those methods are not excluded. [6]<\/p>\n\n\n\n

What Is the Effect on Secondary Patents?<\/strong><\/h3>\n\n\n\n

This is analysis, not a reported statistic. In jurisdictions with large secondary patent families, an expiry map must track many dates for one product. The Philippine rules push the other way. A new salt, polymorph, or formulation needs proof of enhanced efficacy that the prior art did not make inherent. [6] The compound patent therefore carries more weight in the Philippines than it does in a thicket market. The caveat is that formulations and combinations can still qualify when the data support them. [6]<\/p>\n\n\n\n

What Does the Philippines Not Have?<\/strong><\/h2>\n\n\n\n

Is There Patent Linkage in the Philippines?<\/strong><\/h3>\n\n\n\n

No. Chambers states that the patent linkage system was eliminated in 2006. [3] Asia IP reports the same history and says the FDA can approve a registration even when it knows of a valid patent. It lists the Philippines among six Southeast Asian markets with no linkage. [4]<\/p>\n\n\n\n

What Does That Mean for an ANDA-Style Filer?<\/strong><\/h4>\n\n\n\n

There is no list of patents tied to a product, so there is no Orange Book equivalent and no notice-letter step. DPW makes the same point on its Philippines page: it states that the Philippines has no U.S.-style Orange Book, no Paragraph IV procedure, and no broad pharmaceutical patent-term restoration. [15] The patent owner finds the generic in the market or in the import channel, then sues.<\/p>\n\n\n\n

Who Watches for Conflicts?<\/strong><\/h4>\n\n\n\n

BMI, a Fitch Solutions unit, flagged a lack of coordination between IPOPHL and the FDA on patent disputes. [12] Nobody inside the registration process checks the patent. The brand owner must watch the FDA register itself.<\/p>\n\n\n\n

Does the Philippines Have Data Exclusivity?<\/strong><\/h3>\n\n\n\n

The answer has two parts. RA 9502 refers to protection of test data submitted by the original patent holder against unfair commercial use, in line with TRIPS Article 39.3. It sets a 120-day deadline for implementing rules. [1] Chambers states that no specific law or rule covers data or market exclusivity. [3] We found no fixed data-exclusivity term in the sources reviewed. A planner should not assume one.<\/p>\n\n\n\n

Can a Generic Prepare Before Expiry?<\/strong><\/h3>\n\n\n\n

Yes, within limits. Section 72.4 of the IP Code, as amended, exempts testing, making, using, or selling a patented drug solely for purposes reasonably related to developing and submitting information for regulatory approval. The approval can be one required in the Philippines or in another country. [1] The exemption does not cover commercial sales.<\/p>\n\n\n\n

Who Files and Who Gets Granted? What the Statistics Show<\/strong><\/h2>\n\n\n\n

Patent Filings and Grants, 2020 to 2024<\/strong><\/h3>\n\n\n\n

The table shows the IPOPHL numbers as reported through WIPO. [7]<\/p>\n\n\n\n

Year<\/th>Resident filings<\/th>Non-resident filings<\/th>PCT filings<\/th>Total filings<\/th>Resident grants<\/th>Non-resident grants<\/th>Total grants<\/th><\/tr><\/thead>
2020<\/td>419<\/td>271<\/td>2,977<\/td>3,667<\/td>23<\/td>88<\/td>930<\/td><\/tr>
2021<\/td>454<\/td>217<\/td>3,361<\/td>4,032<\/td>44<\/td>168<\/td>1,331<\/td><\/tr>
2022<\/td>498<\/td>233<\/td>3,679<\/td>4,410<\/td>54<\/td>1,281<\/td>1,335<\/td><\/tr>
2023<\/td>724<\/td>206<\/td>3,600<\/td>4,530<\/td>56<\/td>1,527<\/td>1,583<\/td><\/tr>
2024<\/td>807<\/td>258<\/td>3,107<\/td>4,172<\/td>105<\/td>1,958<\/td>2,063<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Source: WIPO CWS annual technical report, Philippines [7]. The source table shows PCT grants only for 2020 and 2021. Totals for 2020 and 2021 include PCT grants. Totals for 2022 to 2024 equal resident plus non-resident grants.<\/p>\n\n\n\n

What We Calculated From the Table<\/strong><\/h4>\n\n\n\n
    \n
  • 2024 non-resident share of grants: 1,958 \/ 2,063 = 94.9%. Resident share: 5.1%. (Our calculation.)<\/li>\n\n\n\n
  • 2024 PCT share of filings: 3,107 \/ 4,172 = 74.5%. (Our calculation.)<\/li>\n\n\n\n
  • Total grants rose from 930 in 2020 to 2,063 in 2024, a factor of 2.2. (Our calculation.)<\/li>\n\n\n\n
  • Resident grants rose from 23 to 105 over the same period, a factor of 4.6. (Our calculation.)<\/li>\n<\/ul>\n\n\n\n

    The table does not split by technology. It cannot tell us how many of the 2,063 grants cover drugs. The press figure for 2025 does: pharmaceuticals led patent filings at 24.9%. [8]<\/p>\n\n\n\n

    \n

    Pharmaceuticals led Philippine patent filings in 2025 at 24.9%, out of 4,486 patent filings in total (IPOPHL data reported by The Philippine Star, April 2, 2026). [8]<\/p>\n<\/blockquote>\n\n\n\n

    Why PCT Entries Matter for Expiry Dates<\/strong><\/h3>\n\n\n\n

    Three-quarters of 2024 filings came through the Patent Cooperation Treaty. That means the filing date, and so the 20-year clock, usually starts at the international filing date. This is our reading of how the PCT works, and the WIPO table does not state it. A planner who wants a Philippine expiry date should start from the international filing date for a PCT entry and then check the national record.<\/p>\n\n\n\n

    Court Cases: What Happens When an Expiry Date Meets a Courtroom<\/strong><\/h2>\n\n\n\n

    Case Study: Phil. Pharmawealth v. Pfizer (Unasyn, Sulbactam-Ampicillin)<\/strong><\/h3>\n\n\n\n

    Pfizer held Philippine Patent No. 21116 on increasing the effectiveness of a beta-lactam antibiotic. It sold sulbactam-ampicillin as Unasyn. Pharmawealth bid to supply the same product to hospitals. [13]<\/p>\n\n\n\n

    What Happened in the Forum<\/strong><\/h4>\n\n\n\n

    Pfizer filed an infringement complaint with the Bureau of Legal Affairs of IPOPHL. The Bureau issued a preliminary injunction in July 2003. Pfizer then went to the Court of Appeals and also filed in the Makati Regional Trial Court. The Court of Appeals issued a restraining order in January 2005. [13]<\/p>\n\n\n\n

    What the Supreme Court Held<\/strong><\/h4>\n\n\n\n

    The Supreme Court decided on November 17, 2010. It held that once the patent expired, Pfizer no longer had a clear right to protect, so the restraining order was improper. It also found forum shopping. It wrote that patentee rights exist “only during the term of the patent” in the sense that the right ends when the patent ends. [13] The practical result: an injunction fight over a patent can outlast the patent.<\/p>\n\n\n\n

    Case Study: Boehringer Ingelheim v. Suhitas (Telmisartan)<\/strong><\/h3>\n\n\n\n

    Boehringer Ingelheim Pharma GmbH and Co sued Suhitas Pharmaceutical Inc. before the Bureau of Legal Affairs (IPV No. 10-2015-00011). The patent, No. 1-1992-43878, covers benzimidazoles including telmisartan. The Bureau decided on June 25, 2021. [14]<\/p>\n\n\n\n

    The Facts That Matter for a Generic Planner<\/strong><\/h4>\n\n\n\n

    Suhitas applied to register generic telmisartan as Misar and Misar-H. It began importing in 2013 after notices from Boehringer. Boehringer bought the products in 2014. [14] The Bureau held the patent valid and infringed. It held that the Cheaper Medicines exemption does not cover imports that do not come from the patent owner or its licensees. [14]<\/p>\n\n\n\n

    The Remedies<\/strong><\/h4>\n\n\n\n

    The Bureau awarded temperate damages of PHP 5.0 million. It issued a permanent injunction covering Misar, Misar-H, and products carrying the generic name telmisartan. It ordered disposal of infringing goods outside commerce. Both parties appealed to the Director General. [14]<\/p>\n\n\n\n

    A Date That Does Not Add Up<\/strong><\/h4>\n\n\n\n

    The article gives the patent expiry as May 10, 2022 in one place and May 5, 2022 in another. [14] The patent number carries the year 1992. If that year is the filing year, a 20-year term would end in 2012, not 2022. We could not resolve this from the sources. The lesson is practical: verify the expiry against the registry record before you plan around it.<\/p>\n\n\n\n

    What the Two Cases Show Together<\/strong><\/h3>\n\n\n\n

    The Bureau decided telmisartan about 10 months before the patent expired (June 25, 2021 to May 2022; our calculation). The case took about six years from the 2015 filing (our calculation). Legal 500 says administrative decisions by the Bureau may come within about six months and that civil IP cases usually take one to two years. [5] Both cases ran longer. A time-to-resolve assumption based on the general guide would understate the real exposure.<\/p>\n\n\n\n

    What Happens After a Patent Expires? The Regulatory Path to a Generic<\/strong><\/h2>\n\n\n\n

    How Long Does FDA Philippines Take to Register a Generic?<\/strong><\/h3>\n\n\n\n

    A regulatory consultancy summary gives working-day targets: up to 120 for full review, 45 for abridged review, and 30 for verification review. A Certificate of Product Registration (CPR) is valid for two or five years at the applicant’s choice. [19] The same source is a marketing article and cites no regulatory text, so confirm the numbers against FDA Philippines guidance.<\/p>\n\n\n\n

    What Did the FDA Promise in 2024?<\/strong><\/h4>\n\n\n\n

    On February 13, 2024, ABS-CBN reported that FDA Director General Samuel Zacate said the approval process would fall from 120 days to 45. The report does not say in the portion we reviewed which approvals the change covers. [18]<\/p>\n\n\n\n

    What Is the Real Timeline?<\/strong><\/h4>\n\n\n\n

    BMI reports an FDA target of 254 days for drug approvals and CPR issuance. It says actual timelines often run two to four years. [12] Two years is 730 days and four years is 1,460 days. Those are 2.9 and 5.7 times the target (our calculation).<\/p>\n\n\n\n

    Why Early Filing Matters Without Linkage<\/strong><\/h3>\n\n\n\n

    The Bolar exemption allows submission work before expiry. [1] No linkage rule blocks the FDA from acting on a filing. [3] A generic maker can therefore build the dossier and hold the registration before the patent ends. The telmisartan case shows the limit: importing and selling before expiry infringed. [14] Registration is allowed. Marketing is not.<\/p>\n\n\n\n

    Parallel Importation: A Narrow Route<\/strong><\/h3>\n\n\n\n

    Section 72.1 as amended by RA 9502 says patent rights do not reach a drug after it has been introduced in the Philippines or anywhere else in the world. Any government agency or private third party may import. [1] The exhaustion regime is international for drugs only. [2] The telmisartan decision limits the route. The Bureau held that the exemption covers only product sourced from the patent owner or its licensees. [14] Cheaper product from a third-party maker does not qualify.<\/p>\n\n\n\n

    Government Use and Compulsory Licenses<\/strong><\/h3>\n\n\n\n

    RA 9502 allows government use in a national emergency or extreme urgency, or when demand for a patented article is not met on reasonable terms. [1] The President’s emergency determination is immediately executory, and only the Supreme Court may issue a restraining order against it. [1] A special compulsory license under Section 93-A permits import mainly for domestic consumption with adequate remuneration to the owner. [1] A non-working license cannot be sought until four years after filing or three years after grant, whichever is later. [2]<\/p>\n\n\n\n

    We did not find a public record of a granted compulsory license for a medicine in the sources reviewed. Treat these tools as available, not as a forecast.<\/p>\n\n\n\n

    Price Regulation: How Much Room Is Left After Expiry?<\/strong><\/h2>\n\n\n\n

    What Do Executive Orders 104 and 155 Do?<\/strong><\/h3>\n\n\n\n

    Executive Order 104, signed on February 17, 2020, imposes a Maximum Retail Price (MRP) or Maximum Wholesale Price on selected drugs. It covers 133 drug formulas and sends 72 more formulas to a technical working group. [9] Executive Order 155, signed on December 7, 2021, extends price regulation to 71 more formulas. It requires the label to carry “RETAIL PRICE NOT TO EXCEED” on a red strip and repeals Executive Order 821 (2009). [10]<\/p>\n\n\n\n

    How Does the Government Pick Drugs?<\/strong><\/h4>\n\n\n\n

    EO 104 gives four selection criteria: leading causes of illness and death, high price gaps against international prices, limited competition, and cases where the innovator product is both the most expensive and the most prescribed or dispensed. [9] The fourth criterion matters to anyone watching an expiry. A brand that keeps its share after expiry at a high price fits the profile.<\/p>\n\n\n\n

    What Are the Penalties?<\/strong><\/h4>\n\n\n\n

    Administrative fines under RA 9502 run from PHP 50,000 to PHP 5,000,000. [1] EO 104 refers violations to RA 9502. [9] The Department of Health must review the covered list every six months. [9]<\/p>\n\n\n\n

    How Wide Is the Brand-to-Generic Price Gap?<\/strong><\/h3>\n\n\n\n

    The Philippine Competition Commission (PCC) compared 2018 retail prices. A 20 mg atorvastatin tablet cost PHP 39.00 as Lipitor, PHP 5.00 for the cheapest branded generic, and PHP 17.75 to PHP 23.00 for unbranded versions. A 50 mg losartan tablet cost PHP 21.00 as Cozaar and PHP 10.50 to PHP 13.55 unbranded. [11]<\/p>\n\n\n\n

    Molecule<\/th>Originator price (PHP)<\/th>Lowest comparator (PHP)<\/th>Highest comparator (PHP)<\/th>Originator multiple (our calculation)<\/th><\/tr><\/thead>
    Atorvastatin 20 mg, versus unbranded<\/td>39.00 (Lipitor)<\/td>17.75<\/td>23.00<\/td>1.7x to 2.2x<\/td><\/tr>
    Atorvastatin 20 mg, versus cheapest branded generic<\/td>39.00 (Lipitor)<\/td>5.00 (Atorbet)<\/td>5.00<\/td>7.8x<\/td><\/tr>
    Losartan 50 mg, versus unbranded<\/td>21.00 (Cozaar)<\/td>10.50<\/td>13.55<\/td>1.5x to 2.0x<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Source for prices: PCC Issues Paper 2020-02 [11]. Multiples are our calculation.<\/p>\n\n\n\n

    The gap between a brand and a generic was already narrow for some molecules before any expiry. For a product with a wide gap, the cap and the generic both pull the price down. Where a molecule sits on this table is a better guide to post-expiry revenue loss than the expiry date alone.<\/p>\n\n\n\n

    Market Structure: Who Competes After Expiry?<\/strong><\/h2>\n\n\n\n

    How Big Is the Philippine Pharmaceutical Market?<\/strong><\/h3>\n\n\n\n

    The PCC cites IQVIA data at PHP 176 billion as of February 2018, with sales of PHP 173.08 billion in 2016 and average growth of 8.3% a year. [11] BMI projects PHP 759 billion by 2030, an implied 7.6% growth rate. [12] If we compound that rate back over five years, the 2025 base is about PHP 526 billion (our calculation, which assumes five years of compounding). The two sources use different scopes and different years, so do not stitch them into one series.<\/p>\n\n\n\n

    Generics Dominate Sales<\/strong><\/h3>\n\n\n\n

    In 2016, generics held 76% of sales. Branded generics held 71% and unbranded generics held 5%. Originators held 24%. [11] Local companies drew about 90% of their sales from branded generics. [11] Multinationals held 56.5% of sales and local firms held 43.5%. [11]<\/p>\n\n\n\n

    What This Means for an Entrant<\/strong><\/h4>\n\n\n\n

    The competitor after expiry is often a branded generic, not an unbranded one. An entrant that plans a plain commodity launch faces a field of marketed brands. United Laboratories held 25.1% of the market in 2016. Pfizer held 6.4%. [11]<\/p>\n\n\n\n

    Where Concentration Is High<\/strong><\/h4>\n\n\n\n

    The PCC measured the Herfindahl-Hirschman Index at 0.0797 for the whole market in 2016, which it treats as unconcentrated. Unbranded generics scored 0.3343, above the 0.25 threshold for high concentration. [11] A segment with few sellers can give a new unbranded entrant more room. This is analysis; the PCC does not draw that conclusion.<\/p>\n\n\n\n

    Import Dependence<\/strong><\/h3>\n\n\n\n

    About 62% of registered drugs were imported in July 2018, against 46.6% in 2011 (100 minus the 53.4% the PCC reports as locally originated; our calculation). The PCC notes that “originated” includes products only packed or labeled locally, and that all API is imported. [11] BMI says the country relies almost fully on imported API, mainly from China and India. It reports a pharmaceutical trade deficit of USD 2.3 billion in 2025. [12] An expiry date does not secure API supply.<\/p>\n\n\n\n

    Case Study: Semaglutide and the Limits of a Global Expiry Map<\/strong><\/h2>\n\n\n\n

    What Is on the Philippine Market Today?<\/strong><\/h3>\n\n\n\n

    Ozempic received FDA approval in 2022 for type 2 diabetes. Wegovy was approved by the Philippine FDA “as early as February” 2024, according to the Inquirer report of June 11, 2025. Novo Nordisk’s medical manager said Ozempic retailed for PHP 7,560 per pen and that Wegovy generally costs about twice as much. [17] A BusinessWorld headline dated April 24, 2026 reports a Wegovy launch in the Philippines. [21]<\/p>\n\n\n\n

    What Does DrugPatentWatch Show for Semaglutide?<\/strong><\/h3>\n\n\n\n

    The public view of DPW’s semaglutide page reports 501 international patents. It lists four national records in the free view: Australia, Brazil, Canada, and China. It shows no Philippine record in that view. The estimated expiry fields require a subscription. [16] We cannot read a Philippine semaglutide expiry date from the free page. A reader who needs one must use the full database or the IPOPHL register.<\/p>\n\n\n\n

    Why This Case Matters for the Map<\/strong><\/h3>\n\n\n\n

    A global article about semaglutide patents will state expiry dates for China, Canada, and Brazil. None of those dates transfers to the Philippines. The Philippine date depends on the Philippine record, the filing date, and whether the claims survive Section 22. The supply problem adds a second layer. Novo Nordisk said the Philippines was among the countries prioritized for supply and that a shortage of Ozempic was “artificial” in the company’s words. [17] Even with a generic registration, a launch also needs API and a price within the caps.<\/p>\n\n\n\n

    What DrugPatentWatch Shows for the Philippines<\/strong><\/h2>\n\n\n\n

    What the Philippines Page Lists<\/strong><\/h3>\n\n\n\n

    DPW states that it analyzes patents covering drugs in 134 countries and calculates likely loss-of-exclusivity dates. [15] Its Philippines page, last updated October 14, 2026, lists three drugs facing expiry from 2026 to 2027. All three dates fall in 2027. [15]<\/p>\n\n\n\n

    Brand (active ingredient)<\/th>Marketer<\/th>DPW estimated key expiry or generic entry<\/th>Patent title as listed<\/th><\/tr><\/thead>
    Kybella (deoxycholic acid)<\/td>AbbVie<\/td>June 19, 2027<\/td>Synthetic Bile Acid Composition, Method, and Preparation<\/td><\/tr>
    Intrarosa (prasterone)<\/td>Millicent<\/td>August 10, 2027<\/td>DHEA Compositions for Treating Menopause<\/td><\/tr>
    Velphoro (sucroferric oxyhydroxide)<\/td>Vifor Fresenius<\/td>November 16, 2027<\/td>Pharmaceutical Compositions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Source: DrugPatentWatch Philippines page [15]. These are DPW estimates. DPW states that the dates are calculated from analysis of known patents and are a rough estimate of generic entry potential. It says the information should not be used as an independent source. [15]<\/p>\n\n\n\n

    How We Read This Page<\/strong><\/h3>\n\n\n\n

    Three notes apply. First, the three-drug list is a view of one filter, not a census of Philippine drug patents. Second, the page lists patent counts of fourteen, three, and eleven for the three products. It does not say whether these counts are Philippine-only or global. [15] Third, the page mentions a Paragraph IV challenge for Kybella while it also states that the Philippines has no Paragraph IV procedure. [15] The challenge most likely refers to the U.S. record. That is our reading, and the page does not say so. Use the page to build a candidate list. Then confirm each date against the Philippine register and the claims.<\/p>\n\n\n\n

    The Five-Gate Model: Turning an Expiry Date Into a Decision<\/strong><\/h2>\n\n\n\n

    This is an original framework from this article. It is not an established industry classification. It asks five questions in order. A product must pass all five before an expiry date becomes a revenue event.<\/p>\n\n\n\n

    Gate 1: Is the Date Real?<\/strong><\/h3>\n\n\n\n

    Check the filing date, the term rule that applies, annual-fee status, and any lapse. A 20-year term runs from filing. [5] An older patent may run 17 years from grant. [13] The telmisartan case shows a date that the sources state in two ways. [14]<\/p>\n\n\n\n

    Gate 2: Is the Scope Narrow Enough?<\/strong><\/h3>\n\n\n\n

    Check whether secondary patents exist on the product and whether Section 22 limits them. [1][6] If the compound patent is the only live patent, the compound date governs. If a formulation patent has passed the efficacy test, add its date.<\/p>\n\n\n\n

    Gate 3: Can You Register in Time?<\/strong><\/h3>\n\n\n\n

    Plan for the target and for the real timeline. File early. The Bolar exemption covers submission work. [1] Use the 30 to 120 working-day targets as the best case and BMI’s two to four years as the stress case. [12][19]<\/p>\n\n\n\n

    Gate 4: Does the Price Leave a Margin?<\/strong><\/h3>\n\n\n\n

    Check whether the molecule is under an MRP and how wide the brand gap is. [9][10][11] A molecule with a narrow gap and a cap leaves little margin for a new entrant.<\/p>\n\n\n\n

    Gate 5: Can You Reach the Buyer and Source the API?<\/strong><\/h3>\n\n\n\n

    Check the competing branded generics, the concentration of the segment, and the API route. [11][12] Branded generics dominate sales, and API comes almost entirely from abroad.<\/p>\n\n\n\n

    Scenario Analysis: Three Paths From Expiry to Shelf<\/strong><\/h3>\n\n\n\n

    The scenarios use the cited timelines. They are our illustrations, not forecasts.<\/p>\n\n\n\n

    Scenario<\/th>Assumption<\/th>Time from filing to CPR (our calculation)<\/th>Source for assumption<\/th><\/tr><\/thead>
    Fast path<\/td>Verification review, 30 working days<\/td>About 6 weeks<\/td>[19]<\/td><\/tr>
    Standard path<\/td>Abridged review, 45 working days<\/td>About 9 weeks<\/td>[19]<\/td><\/tr>
    Full review<\/td>120 working days<\/td>About 24 weeks (5.5 months)<\/td>[19]<\/td><\/tr>
    Stress case<\/td>Actual timelines of two to four years<\/td>24 to 48 months<\/td>[12]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Working days convert at five per week and exclude time spent answering deficiency notices. An applicant who files after expiry loses the head start in every row. An applicant who files two years before expiry has covered even the stress case.<\/p>\n\n\n\n

    What This Means for Different Players<\/strong><\/h2>\n\n\n\n

    What This Means for Generic and Branded-Generic Makers<\/strong><\/h3>\n\n\n\n

    File early and hold the CPR. Do not import or sell before expiry. [14] Check whether a patent that expired still has pending proceedings, because the proceedings may outlive the patent. [13] Price against the cap and against branded generics, not against the originator alone. [10][11]<\/p>\n\n\n\n

    What This Means for Brand Manufacturers<\/strong><\/h3>\n\n\n\n

    No linkage means no notice. [3] Watch the FDA register and the import channel. Expect to start an action after a product appears. The telmisartan decision shows that remedies are available, including a brand-name and generic-name injunction. [14] It also shows a six-year road. Plan the revenue model for the slow case.<\/p>\n\n\n\n

    What This Means for Biosimilars<\/strong><\/h3>\n\n\n\n

    The sources we reviewed give little on biosimilar rules. Chambers states only that biologic patent rights are often more complex because of the nature of the product. [3] We do not publish biosimilar expiry analysis for the Philippines here. A biosimilar planner needs a product-level search of the register.<\/p>\n\n\n\n

    What This Means for Investors and Business Development Teams<\/strong><\/h3>\n\n\n\n

    Treat a Philippine expiry date as an input to a model, not an event. The market is large and growing on BMI’s projection of PHP 759 billion by 2030. [12] The routes to capture it run through registration, price, and channel. Our five gates give a checklist for each target.<\/p>\n\n\n\n

    What This Means for Public Procurement and Policy Teams<\/strong><\/h3>\n\n\n\n

    Government tools exist: parallel importation, government use, and compulsory licensing. [1] Their use depends on facts that a patent date does not show. They also sit alongside the price caps in EO 104 and EO 155. [9][10]<\/p>\n\n\n\n

    What Patent Expirations Cannot Tell You<\/strong><\/h2>\n\n\n\n

    They Cannot Tell You the Launch Date<\/strong><\/h3>\n\n\n\n

    The registration timeline can run from six weeks to four years on the sources above. [12][19]<\/p>\n\n\n\n

    They Cannot Tell You the Price<\/strong><\/h3>\n\n\n\n

    A price cap or a branded-generic field sets the price. [10][11]<\/p>\n\n\n\n

    They Cannot Tell You Who Wins the Market<\/strong><\/h3>\n\n\n\n

    Branded generics held 71% of 2016 sales. [11] A new entrant competes with brands that already have prescriber familiarity. That statement about familiarity is our inference, not a reported finding.<\/p>\n\n\n\n

    They Cannot Tell You Whether the Record Is Accessible<\/strong><\/h3>\n\n\n\n

    IPOPHL declined a request for patent status on two drugs and offered a paid search route. [20] A free list of expiring Philippine drug patents is not available from the source we tested. A commercial database gives an estimate and says so. [15]<\/p>\n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n
      \n
    • Non-residents received 94.9% of the 2,063 patents granted in the Philippines in 2024 (our calculation from [7]).<\/li>\n\n\n\n
    • Pharmaceuticals led Philippine patent filings in 2025 at 24.9%. [8]<\/li>\n\n\n\n
    • The Philippines eliminated patent linkage in 2006 and has no specific data or market exclusivity rules. [3]<\/li>\n\n\n\n
    • Section 22.1 of the IP Code limits patents on new forms of known substances unless they enhance known efficacy. [1]<\/li>\n\n\n\n
    • Regulatory work can start before expiry under Section 72.4. Sales before expiry infringe. [1][14]<\/li>\n\n\n\n
    • Court timelines can exceed patent life. Pharmawealth outlasted the patent by six years and four months (our calculation from [13]).<\/li>\n\n\n\n
    • Two orders cap prices on 204 drug formulas (our sum from [9][10]).<\/li>\n\n\n\n
    • Branded generics held 71% of 2016 sales. [11]<\/li>\n\n\n\n
    • FDA timelines run from a 30 working-day best case to two to four years in practice. [12][19]<\/li>\n\n\n\n
    • DrugPatentWatch’s Philippines page lists three drugs with 2027 estimated expiries and states that its dates are estimates. [15]<\/li>\n<\/ul>\n\n\n\n

      FAQ<\/strong><\/h2>\n\n\n\n

      What is the term of a utility model in the Philippines?<\/strong><\/h3>\n\n\n\n

      A utility model lasts seven years from the filing date and is not renewable. An owner may convert a utility model application into a patent application once, before grant or refusal. [5]<\/p>\n\n\n\n

      Does the Philippines have a Paragraph IV equivalent?<\/strong><\/h3>\n\n\n\n

      No procedure of that kind appears in the sources reviewed. Chambers reports that linkage ended in 2006, and DPW states that the Philippines has no Paragraph IV procedure. [3][15] A patent owner usually learns of a generic when it reaches the market or the import channel.<\/p>\n\n\n\n

      Can a Philippine generic maker import cheaper product from any country while a patent is active?<\/strong><\/h3>\n\n\n\n

      Only if the product was introduced by the patent owner or an authorized party. The Bureau of Legal Affairs held in the telmisartan case that the Cheaper Medicines exemption did not cover unlicensed generic imports. [14]<\/p>\n\n\n\n

      Are new salts and polymorphs patentable in the Philippines?<\/strong><\/h3>\n\n\n\n

      They can be, but only when they differ significantly in efficacy and the improvement is not inherent in the prior art. IPOPHL guidelines require comparative data. [1][6]<\/p>\n\n\n\n

      Can the Philippine government override a drug patent?<\/strong><\/h3>\n\n\n\n

      Yes, under government use (Section 74) and compulsory license provisions (Sections 93 and 93-A) in defined cases such as national emergency or unmet demand. [1] The Supreme Court is the only court that may issue a restraining order against an emergency government-use determination. [1]<\/p>\n\n\n\n

      Which drugs are under a maximum retail price?<\/strong><\/h3>\n\n\n\n

      EO 104 (2020) covers 133 drug formulas and EO 155 (2021) adds 71. The annex lists are in the orders themselves, and the Department of Health reviews them every six months. [9][10]<\/p>\n\n\n\n

      How many Philippine patent filings are pharmaceutical?<\/strong><\/h3>\n\n\n\n

      Pharmaceuticals led 2025 patent filings at 24.9% of 4,486, which is about 1,117 filings by our calculation. [8] The press report does not say how many of these are granted or in force.<\/p>\n\n\n\n

      Where can I check the patent status of a drug in the Philippines?<\/strong><\/h3>\n\n\n\n

      IPOPHL’s response to a 2022 Freedom of Information request pointed to a commercial search service run by its documentation division. [20] Database estimates, including DPW’s, help screen candidates but state that they are not an independent source. [15] Confirm any date against the record.<\/p>\n\n\n\n

      Do the same rules apply to biologics?<\/strong><\/h3>\n\n\n\n

      The same patent statute applies. Chambers notes that biologic patent rights are often more complex. [3] The sources we reviewed give no biosimilar-specific rule, so a product-level review is necessary.<\/p>\n\n\n\n

      How long does a contested patent case take in the Philippines?<\/strong><\/h3>\n\n\n\n

      Practitioner guidance says civil IP cases usually take one to two years and Bureau of Legal Affairs decisions about six months. [5] The telmisartan case took about six years from the 2015 complaint to the 2021 decision. [14] Plan for the slower figure.<\/p>\n\n\n\n

      References<\/strong><\/h2>\n\n\n\n
        \n
      1. Republic Act No. 9502, Universally Accessible Cheaper and Quality Medicines Act of 2008. (2008). Senate of the Philippines. https:\/\/legacy.senate.gov.ph\/republic_acts\/ra%209502.pdf<\/li>\n\n\n\n
      2. Intellectual Property Office of the Philippines. (2012). Reply to the questionnaire on exceptions and limitations to patent rights. World Intellectual Property Organization, Standing Committee on the Law of Patents. https:\/\/www.wipo.int\/en\/web\/scp\/electronic-forum\/exceptions\/replies\/philippines<\/li>\n\n\n\n
      3. Villaraza & Angangco. (2026). Philippines. In Life Sciences and Pharma IP 2026. Chambers and Partners. https:\/\/gpg-pdf.chambers.com\/life-sciences-pharma-ip-litigation-2026\/167\/<\/li>\n\n\n\n
      4. Asia IP. (n.d.). Patent linkage in Asian countries compared to the US. https:\/\/www.asiaiplaw.com\/index.php\/section\/ip-analysts\/patent-linkage-in-asian-countries-compared-to-the-us<\/li>\n\n\n\n
      5. Legal 500. (2024). Country comparative guides 2024: Philippines intellectual property. https:\/\/www.legal500.com\/guides\/wp-content\/uploads\/sites\/1\/2024\/09\/Philippines-Intellectual-Property.pdf<\/li>\n\n\n\n
      6. Intellectual Property Office of the Philippines. (2018, January). Revised guidelines on the examination of pharmaceutical applications involving known substances (QUAMA guide). https:\/\/www.spruson.com\/app\/uploads\/2020\/05\/IPOPHL-Quama-Guide.pdf<\/li>\n\n\n\n
      7. World Intellectual Property Organization. (2024). CWS annual technical report on patent information activities 2024: Philippines. https:\/\/confluence.wipo.int\/confluence\/spaces\/ATR\/pages\/1640671095\/CWS+ATR+PI+2024+PH<\/li>\n\n\n\n
      8. The Philippine Star. (2026, April 2). IP filings hit record high. https:\/\/www.philstar.com\/business\/2026\/04\/02\/2518412\/ip-filings-hit-record-high<\/li>\n\n\n\n
      9. Executive Order No. 104, s. 2020, Improving access to healthcare through the regulation of prices in the retail of drugs and medicines. (2020). Office of the President of the Philippines. https:\/\/lawphil.net\/executive\/execord\/eo2020\/eo_104_2020.html<\/li>\n\n\n\n
      10. Executive Order No. 155, s. 2021. (2021). Office of the President of the Philippines. https:\/\/lawphil.net\/executive\/execord\/eo2021\/eo_155_2021.html<\/li>\n\n\n\n
      11. Reyes, C. M., & Tabuga, A. D. (2020). A profile of the Philippine pharmaceutical industry (PCC Issues Paper No. 2020-02). Philippine Competition Commission. https:\/\/www.phcc.gov.ph\/storage\/pdf-resources\/1678085936_PCC-Issues-Paper-2020-02-A-Profile-of-the-Philippine-Pharmaceutical-Industry.pdf<\/li>\n\n\n\n
      12. BusinessWorld. (2026, March 11). Philippine pharmaceutical market seen at P759 billion by 2030. https:\/\/www.bworldonline.com\/economy\/2026\/03\/11\/735748\/philippine-pharmaceutical-market-seen-at-p759-billion-by-2030\/<\/li>\n\n\n\n
      13. Phil. Pharmawealth, Inc. v. Pfizer, Inc., G.R. No. 167715 (Supreme Court of the Philippines, November 17, 2010). https:\/\/lawyerly.ph\/juris\/view\/c8672<\/li>\n\n\n\n
      14. Managing IP. (n.d.). Philippines: Patent infringement committed in telmisartan case. https:\/\/www.managingip.com\/article\/2a5d0e27ws1xd3j0ltam8\/philippines-patent-infringement-committed-in-telmisartan-case<\/li>\n\n\n\n
      15. DrugPatentWatch. (2026, October 14). Expiring drug patents and generic entry: Philippines. https:\/\/www.drugpatentwatch.com\/p\/expiring-drug-patents-generic-entry\/Philippines<\/li>\n\n\n\n
      16. DrugPatentWatch. (n.d.). Generic semaglutide INN entry, drug patent expiry and freedom to operate. https:\/\/www.drugpatentwatch.com\/p\/generic-api\/SEMAGLUTIDE<\/li>\n\n\n\n
      17. Cabalza, D. (2025, June 11). Novo Nordisk to offer Wegovy weight loss drug in PH this year. Philippine Daily Inquirer. https:\/\/newsinfo.inquirer.net\/2069852\/novo-nordisk-to-offer-wegovy-weight-loss-drug-in-ph-this-year<\/li>\n\n\n\n
      18. ABS-CBN News. (2024, February 13). From 120 to 45 days: FDA to speed up process of drug approval. https:\/\/www.abs-cbn.com\/news\/2024\/2\/13\/-from-120-to-45-days-fda-to-speed-up-process-of-drug-approval-1537<\/li>\n\n\n\n
      19. Maven RS. (2026, May 29). Generic drug registration Philippines. https:\/\/www.mavenrs.com\/blog\/generic-drug-registration-philippines<\/li>\n\n\n\n
      20. Intellectual Property Office of the Philippines. (2022, June 30). Response to FOI request on registered patents and pending applications for etoricoxib and celecoxib (Tracking No. IPOPHL-973857042217). https:\/\/foi.gov.ph\/requests\/list-of-patented-medicines-and-chemical-compositions-for-medical-use-in-the-philippines<\/li>\n\n\n\n
      21. BusinessWorld. (2026, April 24). Novo Nordisk’s weight-loss drug Wegovy launches in PHL. https:\/\/bworldonline.com\/corporate\/2026\/04\/24\/745362\/novo-nordisks-weight-loss-drug-wegovy-launches-in-phl\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        In 2024, the Intellectual Property Office of the Philippines (IPOPHL) granted 2,063 patents. Non-residents received 1,958 of them. That is […]<\/p>\n","protected":false},"author":1,"featured_media":39914,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39913"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39913\/revisions"}],"predecessor-version":[{"id":39915,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39913\/revisions\/39915"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39914"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}